Carmat - Update on achievements and FY24 outlook
Carmat provided an unexpected update on its achievements and outlook. 3 main elements: 1/ Carmat is missing FY23 guidance with revenues landing at EUR 2.8m vs. guidance of EUR 4-6m in H2 23. 2/ Improving commercial dynamics in Q4 23 with management guiding for FY24e revenues to land between EUR 14-20m (DPe EUR 15m). 3/ Carmat announces the launch of a capital increase “in the very near future”. Based on recent news, we have put our rating and TP under review and will come back shortly with an update.Carmat is focused on the research and development of an innovative product in the medical sector, developing an orthotopic and biocompatible artificial heart which is completely implantable, as well as its electrical power supply system and remote diagnosis system. Co. is developing a long-term therapeutic solution for patients who suffer from advanced bi-ventricular heart failure and who are not eligible for cardiac transplantation and who have exhausted all drug possibilties. Co. is still in the phase of research and development and thus do not generate any revenues.
We are an investment house with Belgian roots founded on more than 150 years of trust.
As a private company owned by long-term committed shareholders, we are independent. Naturally and structurally. Our experts have the knowledge to think and act without bias, and to make decisions that benefit our clients. Today and tomorrow.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.